These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37391055)

  • 1. A Randomized Parallel-group Study of Digital Gut-directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome.
    Berry SK; Berry R; Recker D; Botbyl J; Pun L; Chey WD
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3152-3159.e2. PubMed ID: 37391055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: A retrospective evaluation.
    Peters SL; Gibson PR; Halmos EP
    Neurogastroenterol Motil; 2023 Apr; 35(4):e14533. PubMed ID: 36661117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
    Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
    Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D.
    Eswaran SL; Chey WD; Han-Markey T; Ball S; Jackson K
    Am J Gastroenterol; 2016 Dec; 111(12):1824-1832. PubMed ID: 27725652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mourey F; Decherf A; Jeanne JF; Clément-Ziza M; Grisoni ML; Machuron F; Legrain-Raspaud S; Bourreille A; Desreumaux P
    World J Gastroenterol; 2022 Jun; 28(22):2509-2522. PubMed ID: 35979259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
    Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
    Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial.
    Rutten JMTM; Vlieger AM; Frankenhuis C; George EK; Groeneweg M; Norbruis OF; Tjon A Ten W; van Wering HM; Dijkgraaf MGW; Merkus MP; Benninga MA
    JAMA Pediatr; 2017 May; 171(5):470-477. PubMed ID: 28346581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial.
    Di Nardo G; Bernardo L; Cremon C; Barbara G; Felici E; Evangelisti M; Ferretti A; Furio S; Piccirillo M; Coluzzi F; Parisi P; Mauro A; Di Mari C; D'Angelo F; Mennini M
    Nutrition; 2024 Jun; 122():112397. PubMed ID: 38479039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
    Mack I; Schwille-Kiuntke J; Mazurak N; Niesler B; Zimmermann K; Mönnikes H; Enck P
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1039-1047.e9. PubMed ID: 34214682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.